<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531999</url>
  </required_header>
  <id_info>
    <org_study_id>SSAT023</org_study_id>
    <nct_id>NCT00531999</nct_id>
  </id_info>
  <brief_title>Raltegravir Insulin Sensitivity Study</brief_title>
  <official_title>An Open Label Study of the Impact on Insulin Sensitivity, Lipid Profile and Vascular Inflammation by Treatment With Lopinavir / Ritonavir (400 / 100 mg Twice Daily) or Raltegravir 400 mg Twice Daily in HIV Negative Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Stephens Aids Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Stephens Aids Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to look at the effects of two different HIV medications on the&#xD;
      body's response to insulin (a hormone that regulates blood sugar levels). This will be done&#xD;
      using a method called the 'euglycaemic clamp'&#xD;
&#xD;
      The study will also investigate the effects of these drugs on blood fats and on circulating&#xD;
      markers in the blood stream related to blood vessels (vascular inflammation markers).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo four euglycaemic clamp procedures in order to determine the extent of&#xD;
      glucose disposal. The first clamp will be performed prior to the commencement of the first&#xD;
      study drug administration, the second one following two weeks of study drug, the third after&#xD;
      a two week washout period, prior to commencement of second study drug administration and the&#xD;
      fourth after two weeks of the second study drug&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in insulin sensitivity by euglycaemic clamp method</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum levels of fasting cholesterol, triglycerides</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Raltegravir 400 mg twice daily for the first 14 days of the study. Lopinavir/ritonavir 400/100 mg twice daily for the last 14 days of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lopinavir/ritonavir 400/100 mg twice daily for the first 14 days of the study.&#xD;
Raltegravir 400 mg twice daily for the last 14 days of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir then lopinavir/ritonavir</intervention_name>
    <description>raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir then raltegravir</intervention_name>
    <description>lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have documented negative HIV serology by ELISA and P24 antigen&#xD;
&#xD;
          -  Subjects must be clinically well males aged between 18 to 60 years&#xD;
&#xD;
          -  Fasting blood glucose, total cholesterol and triglycerides within normal limits&#xD;
&#xD;
          -  Hepatic transaminases (AST and ALT) ≤ 3 × upper limit of normal (ULN)&#xD;
&#xD;
          -  Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm3; platelets ≥&#xD;
             50,000/mm3; hemoglobin ≥ 8.0 g/dL)&#xD;
&#xD;
          -  Serum amylase ≤ 1.5 × ULN (subjects with serum amylase &gt; 1.5 × ULN will remain&#xD;
             eligible if pancreatic lipase is ≤ 1.5 × ULN)&#xD;
&#xD;
          -  Sexually active males must use condoms during the course of the study&#xD;
&#xD;
          -  Life expectancy ≥ 1 year&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a waist hip ratio &gt; 0.97 or BMI &gt; 28 kg/m2 will be excluded&#xD;
&#xD;
          -  Acute or chronic hepatitis B infection (determined by positive hepatitis B surface&#xD;
             antigen result at the screening visit)&#xD;
&#xD;
          -  Acute or chronic hepatitis C infection (determined by positive hepatitis C antibody&#xD;
             result at the screening visit)&#xD;
&#xD;
          -  Other metabolic syndrome or disease process in the opinion of the investigator likely&#xD;
             to cause marked disturbance in glucose and lipid homeostasis including hypertension&#xD;
&#xD;
          -  Receiving on-going therapy with any of the following:&#xD;
&#xD;
               -  Metabolically active medications&#xD;
&#xD;
               -  Any lipid-lowering medication&#xD;
&#xD;
               -  Hormonal agents (oestrogens or androgens)&#xD;
&#xD;
               -  Glucocorticoids&#xD;
&#xD;
               -  Beta-blockers&#xD;
&#xD;
               -  Thiazide diuretics&#xD;
&#xD;
               -  Thyroid preparations&#xD;
&#xD;
               -  Psychotropic agents&#xD;
&#xD;
               -  Anabolic steroids&#xD;
&#xD;
               -  Megestrol acetate&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greame Moyle</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chelsea &amp; Westminser Healthcare NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Stephens Centre, Chelsea &amp; Westminster Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2007</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Graeme Moyle</name_title>
    <organization>St Stephen's AIDS Trust</organization>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>Euglycaemic clamp</keyword>
  <keyword>healthy volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

